Nichola Hawes is on trial for alleged fraud and selling or supplying medicines without proper prescriptions.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most Americans.

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating."

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived deal for consumers.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The tele-health company Hims & Hers Health is facing scrutiny after critics say its Super Bowl ad promotes weight loss drugs that are not FDA-approved.